Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies

BACKGROUND: Talazoparib (BMN673) is a new poly(ADP-ribose) polymerase inhibitor that has been FDA approved for patients suffering from metastatic breast cancer with germline BRCA mutations. METHOD AND RESULTS: In the current study, an accurate and efficient liquid chromatography-tandem mass spectrom...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Drug Des Devel Ther
Main Authors: Attwa, Mohamed W, Kadi, Adnan A, Abdelhameed, Ali S, Alhazmi, Hassan A
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7049284/
https://ncbi.nlm.nih.gov/pubmed/32158196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S239458
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados